Oxybutynin IVR - Juniper Pharmaceuticals

Drug Profile

Oxybutynin IVR - Juniper Pharmaceuticals

Alternative Names: JNP 0101; JNP-0101 intravaginal ring; Oxybutynin IVR

Latest Information Update: 11 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Juniper Pharmaceuticals
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Overactive bladder

Most Recent Events

  • 11 Jan 2017 Juniper Pharmaceuticals announces intention to submit IND application for oxybutynin to the US FDA in 2017 (Juniper Pharmaceuticals website, January 2017)
  • 15 Nov 2016 Juniper Pharmaceuticals completes preclinical pilot study in Overactive bladder in USA
  • 11 Jan 2016 Juniper plans a phase III trial for Overactive bladder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top